A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus—A possible reference for coronavirus disease‐19 treatment option
Open Access
- 27 February 2020
- journal article
- review article
- Published by Wiley in Journal of Medical Virology
- Vol. 92 (6), 556-563
- https://doi.org/10.1002/jmv.25729
Abstract
In the past few decades, coronaviruses have risen as a global threat to public health. Currently, the outbreak of coronavirus disease‐19 (COVID‐19) from Wuhan caused a worldwide panic. There are no specific antiviral therapies for COVID‐19. However, there are agents that were used during the SARS and MERS epidemics. We could learn from SARS and MERS. Lopinavir (LPV) is an effective agent that inhibits the protease activity of coronavirus. In this review, we discuss the literature on the efficacy of LPV in vitro and in vivo, especially in patients with SARS and MERS, so that we might clarify the potential for the use of LPV in patients with COVID‐19.Funding Information
- National Natural Science Foundation of China (81870417)
This publication has 28 references indexed in Scilit:
- Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi ArabiaThe New England Journal of Medicine, 2012
- Molecular dynamic simulations analysis of ritronavir and lopinavir as SARS-CoV 3CLpro inhibitorsJournal of Theoretical Biology, 2008
- In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compoundsJournal of Clinical Virology, 2004
- HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirusBiochemical and Biophysical Research Communications, 2004
- Old drugs as lead compounds for a new disease? Binding analysis of SARS coronavirus main proteinase with HIV, psychotic and parasite drugsBioorganic & Medicinal Chemistry, 2004
- Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findingsThorax, 2004
- SARS: epidemiologyRespirology, 2003
- SARS virus infection of cats and ferretsNature, 2003
- Clinical use of lopinavir/ritonavir in a salvage therapy settingAIDS, 2002
- LopinavirDrugs, 2000